|From: singhtelecom (Rep: 971)||Date: 05/04/2019 02:05|
|Forum: Idera Pharmaceuticals - Msg #788||Thread #674080084 (Rec: 0) |
|we believe that our available funds will be sufficient to enable perform the following:|
complete enrollment, where applicable, and continue to execute on:
the Phase 1 portion of our ongoing Phase 1/2 clinical trial of tilsotolimod in combination with pembrolizumab in anti-PD1 refractory melanoma (ILLUMINATE-204);
the Phase 2 portion of our ongoing Phase 1/2 clinical trial of tilsotolimod in combination with ipilimumab in anti-PD1 refractory melanoma (ILLUMINATE-204);
the Phase 3 clinical trial of tilsotolimod in combination with ipilimumab for the treatment of anti-PD1 refractory metastatic melanoma (ILLUMINATE-301); and
the Phase 1b monotherapy clinical trial of tilsotolimod in multiple refractory tumor types (ILLUMINATE-101);
initiate our Phase 2 study of tilsotolimod in combination with nivolumab and ipilimumab for the treatment of certain solid tumors (ILLUMINATE-206) ;
fund certain investigator initiated clinical trials of tilsotolimod; and
maintain our current level of general and administrative expenses in order to support the business .
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.